MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock
$60,881K
Proceeds from stock
option exercises
$1,252K
Net cash provided by
financing activities
$61,140K
Canceled cashflow
$993K
Net (decrease)
increase in cash, cash...
$10,727K
Canceled cashflow
$50,413K
Issuance costs
associated with financings
$993K
Stock-based compensation
expense
$6,898K
Depreciation
$270K
Amortization of premium
(accretion of discount) on...
-$162K
Maturities of investments
$60,000K
Net cash used in
operating activities
-$32,438K
Net cash (used in)
provided by investing...
-$17,975K
Canceled cashflow
$7,330K
Canceled cashflow
$60,000K
Net loss
-$35,767K
Purchases of investments
$77,973K
Accounts payable and
accrued other...
-$3,322K
Prepaid expenses and
other assets
$679K
Acquisitions of property and
equipment
$2K
Back
Back
Cash Flow
Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC)
source: myfinsight.com